Safety and Efficacy of Glucagon‐Like Peptide‐1 Receptor Agonists Use in Elderly People With Obesity—A Meta‐Analysis
Pooled result · Serious adverse eventsResult — go to the resultPooled LOR 0.06Authors' conclusion
GLP-1 RA therapy seems to be safe and effective in older adults with obesity, achieving similar effects on weight loss and glycemic control as in younger individuals.
Study context
- Population
- Adults ≥65 years with obesity with or without T2D treated with GLP-1 RA, compared with younger individuals
- Participants
- 1,229 adults5 studies
- Comparison
- GLP-1 RA in older vs younger adults with obesity
- Outcome
- Serious adverse events
Methodological detailsPRISMA, random effects, equivalence testing via two one-sided tests (TOST), meta-regression
- PRISMA
- Random effects
- Equivalence testing via TOST
- Meta-regression
Pooled result
As reported in the abstract
Pooled log odds ratios (LOR)
0.06
P = 0.9
Further pooled results
Metabolic and weight control efficacy
- Efficacy in metabolic and weight control was comparable
Fat mass and sarcopenia (one study, liraglutide)
- One study suggested liraglutide could reduce fat mass without worsening sarcopenia
Safety
| Outcome | LOR | P value |
|---|---|---|
| NauseaTrend toward lower frequency | −0.44 | P = 0.06 |
| Constipation | 0.72 | P = 0.02 |
| Hypoglycemia | 0.97 | P < 0.001 |
Original publication
Safety and Efficacy of Glucagon‐Like Peptide‐1 Receptor Agonists Use in Elderly People With Obesity—A Meta‐Analysis. Obesity (Silver Spring). Published 4 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →